Reviparin sodium

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Reviparin sodium
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
?
Identifiers
CAS number 9041-08-1 YesY
ATC code B01AB08
KEGG D06398 YesY
Chemical data
Formula ?
 N (what is this?)  (verify)

Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins.

Pharmacodynamic[edit]

Reviparin is a low molecular weight heparin (LMWH) obtained by nitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 daltons.

Indications[edit]

  • Prophylaxis of deep vein thrombosis (DVT)
  • Prophylaxis of perioperative thromboembolism[1][2]
  • Treatment of DVT with or without pulmonary embolism (PE)[3]
  • Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA)[4][5]

References[edit]

  1. ^ Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin". Thromb. Res. 81 (2 Suppl): S39–45. PMID 8822126. 
  2. ^ Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery". Semin. Thromb. Hemost. 25 Suppl 3: 79–82. PMID 10549720. 
  3. ^ Gore M, Kelkar P, Rege N, Ross C (October 2004). "Reviparin sodium clivarine: a review of its therapeutic use". J Indian Med Assoc 102 (10): 589–90, 592. PMID 15887830. 
  4. ^ Preisack MB, Karsch KR (December 1993). "Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty". Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8; discussion S59–60. PMID 8180331. 
  5. ^ Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996). "Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation". J. Am. Coll. Cardiol. 28 (6): 1437–43. doi:10.1016/s0735-1097(96)00343-9. PMID 8917255. Retrieved 2014-09-18. 

External links[edit]

  • reviparin at the US National Library of Medicine Medical Subject Headings (MeSH)
  • Yusuf S, Mehta SR, Xie C, et al. (2005). "Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation". JAMA 293 (4): 427–35. doi:10.1001/jama.293.4.427. PMID 15671427.